scholarly journals Characterization of a “low-risk” cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database

2017 ◽  
Vol 24 (8) ◽  
pp. 611-617 ◽  
Author(s):  
Kathleen F McGinley ◽  
Xizi Sun ◽  
Lauren E Howard ◽  
William J Aronson ◽  
Martha K Terris ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Low Risk ◽  
Equal Access ◽  
Grade Group ◽  
Hospital Database ◽  
Cancer Hospital ◽  
Group 2

scholarly journals Cribriform architecture outperforms percent Gleason pattern 4 and tertiary pattern 5 in predicting outcome of Grade group 2 prostate cancer patients

2021 ◽  
Author(s):  
Neslisah Seyrek ◽  
Eva Hollemans ◽  
Susanne Osanto ◽  
Rob C. M. Pelger ◽  
Henk G. van der Poel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Grade Group ◽  
Gleason Pattern ◽  
Predicting Outcome ◽  
Group 2

PD34-07 CAN GLEASON 7 PROSTATE CANCER EVER BE LOW-RISK? RESULTS FROM THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Kathleen McGinley ◽  
Xizi Sun ◽  
Lauren Howard ◽  
William Aronson ◽  
Martha Terris ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Low Risk ◽  
Equal Access ◽  
Cancer Hospital

scholarly journals Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database

Cancer ◽  
2015 ◽  
Vol 122 (2) ◽  
pp. 222-229 ◽  
Author(s):  
Brian T. Hanyok ◽  
Lauren E. Howard ◽  
Christopher L. Amling ◽  
William J. Aronson ◽  
Matthew R. Cooperberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Equal Access ◽  
Castration Resistant Prostate Cancer ◽  
Hospital Database ◽  
Castration Resistant ◽  
Cancer Hospital

MP81-06 RADIOMIC FEATURES OF PROSTATE CANCER PATIENTS (GLEASON GRADE GROUP = 2) SHOW DIFFERENCES BETWEEN AFRICAN AMERICAN AND CAUCASIAN POPULATIONS ON BI-PARAMETRIC MRI

2020 ◽  
Vol 203 ◽  
pp. e1238
Author(s):  
Rakesh Shiradkar* ◽  
Amr Mahran ◽  
Shivam Sharma ◽  
Britt Conroy ◽  
Sree Harsha Tirumani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Patients ◽  
Gleason Grade ◽  
Grade Group ◽  
Group 2

PELVIC LYMPH NODE DISSECTION SHOULD BE OMITTED IN LOW RISK PROSTATE CANCER PATIENTS. RESULTS OF A MATCHED ANALYSIS

2009 ◽  
Vol 181 (4S) ◽  
pp. 756-757
Author(s):  
Alberto Briganti ◽  
Alexander Haese ◽  
Umberto Capitanio ◽  
Andrea Gallina ◽  
Felix K h Chun ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Dissection ◽  
Pelvic Lymph Node Dissection ◽  
Low Risk ◽  
Pelvic Lymph Node ◽  
Node Dissection ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer

A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients

2016 ◽  
Vol 35 (2) ◽  
pp. 189-197 ◽  
Author(s):  
Sami-Ramzi Leyh-Bannurah ◽  
Paolo Dell’Oglio ◽  
Zhe Tian ◽  
Jonas Schiffmann ◽  
Shahrokh F. Shariat ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Low Risk ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer

scholarly journals Characterization of fecal microbiome in biopsy positive prostate cancer patients

BJUI Compass ◽  
2021 ◽  
Author(s):  
Ran Katz ◽  
Muhamad Abu Ahmed ◽  
Ali Safadi ◽  
Wasiem Abu Nasra ◽  
Alexander Visoki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Fecal Microbiome

scholarly journals Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy

2014 ◽  
Vol 47 (2) ◽  
pp. 89-93 ◽  
Author(s):  
Carlos Antônio da Silva Franca ◽  
Sérgio Lannes Vieira ◽  
Antonio Carlos Pires Carvalho ◽  
Antonio Jose Serrano Bernabe ◽  
Antonio Belmiro Rodrigues Campbell Penna
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Biochemical Recurrence ◽  
Disease Free Survival ◽  
Disease Recurrence ◽  
Recurrence Rates ◽  
Psa Nadir ◽  
Group 2 ◽  
Iodine 125 ◽  
Group 1

Objective To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.

Sign in / Sign up

Export Citation Format

Share Document